A chronic hyperactivated angiogenic state in cancer plays an important role in tumour growth and metastasis and has been identified as one of the hallmarks of cancer. Inhibition of this process has been associated with tumour suppression in many pre-clinical contexts using different animal tumour models. Anti-angiogenic therapeutics were subsequently developed and used to treat several prevalent types of human cancer. However, recent clinical experience has revealed limitations of this approach in treating cancer as patient response varies over a wide range. Given that there are complex underlying molecular and cellular changes provoked by anti-angiogenic treatment within the tumour microenvironment (TME), it is not surprising that modest effectiveness and resistance have been observed in the clinical setting. This article discusses these issues in the context of VEGF-A-targeted anti-angiogenic treatment of cancer and provides insight into the importance of tumour endothelium for understanding the tumour response to anti-angiogenic therapy. Special consideration is also given to possible approaches for investigating how endothelium contributes to the tumour response to anti-angiogenic agents and for exploring the therapeutic and biomarker potential of targeting tumour endothelium.
Skip Nav Destination
Article navigation
December 2014
-
Cover Image
Cover Image
- PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkTable of Contents
Conference Article|
November 17 2014
Exploring the role of endothelium in the tumour response to anti-angiogenic therapy
Yi-Chao He;
Yi-Chao He
*Tumour Angiogenesis Program, Peter MacCallum Cancer Centre, East Melbourne, Victoria 3002, Australia
†Sir Peter MacCallum Department of Oncology, The University of Melbourne, Victoria 3010, Australia
Search for other works by this author on:
Michael M. Halford;
Michael M. Halford
*Tumour Angiogenesis Program, Peter MacCallum Cancer Centre, East Melbourne, Victoria 3002, Australia
Search for other works by this author on:
Marc G. Achen;
Marc G. Achen
*Tumour Angiogenesis Program, Peter MacCallum Cancer Centre, East Melbourne, Victoria 3002, Australia
†Sir Peter MacCallum Department of Oncology, The University of Melbourne, Victoria 3010, Australia
Search for other works by this author on:
Steven A. Stacker
Steven A. Stacker
1
*Tumour Angiogenesis Program, Peter MacCallum Cancer Centre, East Melbourne, Victoria 3002, Australia
†Sir Peter MacCallum Department of Oncology, The University of Melbourne, Victoria 3010, Australia
1To whom correspondence should be addressed (emailsteven.stacker@petermac.org).
Search for other works by this author on:
Publisher: Portland Press Ltd
Received:
June 12 2014
Online ISSN: 1470-8752
Print ISSN: 0300-5127
© The Authors Journal compilation © 2014 Biochemical Society
2014
Biochem Soc Trans (2014) 42 (6): 1569–1575.
Article history
Received:
June 12 2014
Citation
Yi-Chao He, Michael M. Halford, Marc G. Achen, Steven A. Stacker; Exploring the role of endothelium in the tumour response to anti-angiogenic therapy. Biochem Soc Trans 1 December 2014; 42 (6): 1569–1575. doi: https://doi.org/10.1042/BST20140173
Download citation file:
Sign in
Don't already have an account? Register
Sign in to your personal account
You could not be signed in. Please check your email address / username and password and try again.
Captcha Validation Error. Please try again.